Purpose: To evaluate injection site reactions and pain following paliperidone palmitate 1-month (PP1M) and 3-month (PP3M) administration using safety data of double-blind (DB), noninferiority study. Findings: PP1M and PP3M injections were well tolerated. Incidence of induration, redness, and swelling were low in both phases (OL: 9-12%; DB: 7-13%), and were mostly mild in both groups.
INTRODUCTION
Schizophrenia is a chronic disorder requiring life-long treatment with antipsychotics. This raises the concern of patient adherence to the treatment. 1 Although use of long-acting injectable (LAI) antipsychotics have improved treatment adherence in schizophrenia, first generation LAI antipsychotics, especially the oil-based formulations (e.g., fluphenazine decanoate and haloperidol decanoate) are associated with significant injection site reactions and pain. 2 Repeated largevolume administrations of these oil-based injections are associated with muscle granuloma, fibrosis, and accumulation of oil, 3 which ultimately cause reluctance in patients toward these medications and thus lead to treatment discontinuation and symptomatic relapse. 4 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Newer generation LAI antipsychotics, including paliperidone palmitate 1-month (PP1M), have minimal injection site pain, possibly due to their aqueous based formulations. 5, 6 A more recently introduced LAI, paliperidone palmitate 3-month (PP3M), which offers a substantially longer dosing interval of once every 3 months, is approved in the United States, 7 Europe, and in other countries for the treatment of schizophrenia in patients previously treated with PP1M. PP3M can be administered in the deltoid or the gluteal with a preference for deltoid injections due to easy access, and less embarrassment associated with exposure of the gluteal area. PP3M is 1.75 times the volume of an equivalent dose of PP1M, yielding volumes from 0.875 to 2.625 mL.
Many nursing guidelines specify that injection volume for deltoid administration should not exceed 2 mL. 8, 9 However, a review of 531 F I G U R E 1 Study design. PP1M: paliperidone palmitate 1 month formulation; PP3M: paliperidone palmitate 3 month formulation. a Patients received PP1M on day 1 (150 mg-eq deltoid), day 8 (100 mg-eq deltoid), followed by flexible dosing administered at weeks 5 and 9. b PP3M doses: 3.5-fold of the respective PP1M doses. Doses of paliperidone palmitate can be expressed in mg-eq of paliperidone (active moiety) or mg of paliperidone palmitate. PP1M doses expressed as 50, 75, 100, and 150 mg-eq are equal to 78, 117, 156, and 234 mg of paliperidone palmitate, respectively. PP3M doses expressed as 175, 263, 350, and 525 mg-eq are equal to 273, 410, 546, and 819 mg of paliperidone palmitate, respectively injection administration guidelines reveals that injection volume best practice guidelines are not based on controlled clinical trials and hence not clearly defined. 10 This indicates the need for more evidence-based research to support the administration of larger-volume injections in the deltoid muscle. Given the difference in formulations, the incidence and severity of injection site reactions and pain associated with LAI antipsychotics and patient preference for injection site are of interest to health care professionals.
Results from two long-term, multicenter phase 3 studies have demonstrated that a larger proportion of patients with schizophrenia who were adequately stabilized with PP1M for at least 4 months and subsequently treated with PP3M (doses 175, 263, 350, or 525 mg-eq), did not experience a significant return of schizophrenia symptoms 11 and PP3M was noninferior to PP1M with similar relapse rates in both groups. 12 The current analysis was conducted to evaluate the frequency of injection site reaction and pain following administration of PP1M and PP3M formulations using safety data of a randomized, double-blind (DB), parallel group, multicenter, noninferiority study (NCT01515423). 12 
METHODS
Safety data for injection site reaction and pain analysis were collected from a phase 3, randomized, DB, parallel-group, multicenter, noninferiority study conducted at 199 sites across 26 countries from April 2012 to March 2015. The primary study results are published elsewhere. 12 In brief, the study enrolled adult (18-70 years old) patients of either The study protocol and amendments were reviewed by an Independent Ethics Committee or Institutional Review Board for each site. The study was conducted in compliance with the Declaration of Helsinki and applicable regulatory requirements. Written informed consent was obtained from all patients before study enrollment. (11) 48 (10) 44 (9) 92 (9) PP1M, paliperidone palmitate one month formulation; PP3M, paliperidone palmitate 3 month formulation. a One patient in treatment group PP1M had injection site data as missing, and is not included in the 
Study design and treatment

Assessments
Injection site reaction and pain assessments were carried out within All injection site adverse events (AEs) with objective findings (e.g., swelling, redness, induration) and a severity assessment of "moderate" or "severe" were photographed along with a metric ruler for later review. Follow-up photographs were taken until the AE resolved or until the severity assessment was "mild." In the event an AE related to the injection site that involved suspected cellulitis or abscess were observed, patients would be referred to a dermatologist or surgeon for consideration of incision and drainage procedure along with tissue microbiological samples. If nodules, fibroma, furuncle or other noninfectious reaction with a severity assessment of either "moderate"
or "severe," occurred patients would be referred to a dermatologist or surgeon for consideration of fine needle aspiration and/or tissue biopsy. All injection site AEs were followed for any clinically significant abnormalities persisting at the end of the study until resolution or until they reached a clinically stable endpoint.
Statistical methods
The VAS scores and injection site reactions were summarized using descriptive statistics. 
RESULTS
Demographics and injection site selection
Of 1,716 screened patients, 1,429 patients entered the OL phase and 1,016 patients were randomized in the DB phase. The primary efficacy findings are published elsewhere. 12 Of these, 1,279 patients in OL phase and 1,015 patients in DB phase had injection site data available and were included for injection site reaction and pain analysis ( Table 1) .
As per protocol requirements, all injections on day 1 and week 1 during the OL phase were to be administered in deltoid; accordingly, more than 99% of patients received PP1M injections in the deltoid region on day 1 and week 1 during the OL phase. The proportion of patients with injections in the deltoid region was higher than in the gluteal region at week 5 (66% vs. 34%), at week 9 (64% vs. 36%), and at week 13 (62% vs. 38%) in the OL phase. Overall, majority of the VAS score in the PP3M-treated group was slightly higher than the PP1M-treated group that was eliminated by the last injection cycle; the mean (SD) VAS scores decreased from DB baseline to DB endpoint in 
Injection site pain
Injection site-related treatment-emergent adverse events
Injections were well tolerated in both the OL and DB treatment phases (Table 2) . None of the injection site-related treatment-emergent adverse events (TEAEs) were reported as a serious AE during the study.
No severe ratings were reported for any injection site adverse reaction during the DB phase. Overall, 13% of patients in OL phase had spontaneously reported injection site reactions; 6% patients in the PP1M treatment group and 8% of patients in the PP3M group had spontaneously reported injection site reactions during the DB phase (Table 2) .
One patient had a hypersensitivity reaction (systemic allergic reaction as evidenced by hives) 3 days after the first initiation dose of PP1M
(150 mg-eq deltoid). The skin biopsy revealed it as "perivascular lymphocytic inflammation with rare eosinophils" and the findings were compatible with the clinical impression of urticaria. The patient was withdrawn from the study. This patient's biopsy was the only known injection site related biopsy taken during the study.
Treatment-emergent injection site induration, redness and swelling were observed in ≤6% of patients in the OL phase and were mild in nature. During the DB phase, local injection site tolerability was similar in both treatment groups (PP3M and PP1M). Treatment-emergent induration, redness, and swelling were observed in ≤5% of patients in both treatment groups and were mostly mild in nature. The level of induration, redness, and swelling as rated by the investigator was generally similar between the PP3M and PP1M groups ( Table 2) .
One patient treated with PP3M (525 mg-eq) had onset of panniculitis as a mild severity AE on day 217, which was resolved 71 days later (previous PP3M gluteal injection was on day 204). The patient tolerated two further PP3M injections without AE and completed the study without a relapse. The other PP3M-treated patient (525 mg-eq) had onset of injection site swelling as a moderate severity AE on day 384, which was resolved 52 days later (previous PP3M deltoid injection was on day 372). The patient tolerated the previous three injections of 525 mg-eq PP3M with all injection site ratings as absent for induration, redness, and swelling and pain ratings of 12 (out of 100) or less for each injection.
Two patients (0.1%) were discontinued from the study due to injection site pain in OL phase; no patient was discontinued due to injection site pain as AE in the DB phase. During the OL phase, one patient had pain measured as "severe reaction" from day 1; however, no photograph was taken and the patient continued in the study.
DISCUSSION
Data from the present study demonstrated that injection site pain and injection site reactions associated with PP3M administration were infrequent. Both PP1M and PP3M injections reported of minimal and similar injection site reactions and pain in patients with schizophrenia.
Mean VAS scores were comparable between both treatment groups. This is consistent with an earlier study conducted in PP, which demonstrated that PP may be associated with lower mean pain severity than other first-generation products. 13 It should be noted that injection site pain and reactions were self-evaluated by patients and scored on VAS by patients only, without technical evaluation by the physicians.
Higher doses of PP3M (and therefore larger injection volumes)
were not associated with an increased incidence of injection site pain or injection site reactions in either the deltoid or the gluteal muscle.
Previous studies have revealed that both deltoid and gluteal sites are comparable in term of safety and tolerability. 10, 11 Moreover, in both OL and DB phases of study, more patients received injections in the deltoid muscle than gluteal muscle. Although injection site selection was at investigator's discretion, patients have a tendency to prefer to take injections on the deltoid muscle site than gluteal muscle, as it is less socially embarrassing. 8 PP (both PP1M and PP3M) is a low water soluble nanocrystal suspension. Good injection technique (proper administration into striated muscle fibers, slow injection, sufficient shaking of the suspension moderate. These reactions started to subside as study progressed, probably because of acclimatization of patients to the injections.
CONCLUSION
Injection site reactions and pain were low and mild, and were similar between PP1M and PP3M, regardless of the dose, volume of injection and location of the injection. Based on these efficacy and safety data, nursing guidelines for preference of deltoid injections and large volume should be re-evaluated for treating patients with LAIs. PP3M can be considered as the LAI antipsychotic of longest duration currently available that requires the patient to visit outpatient clinics only four times a year for an injection rather than every 2 weeks or monthly. The PP3M injection schedule would be expected to facilitate treatment access and medication adherence among patients with schizophrenia.
